Total Payments
$9,089
2024 Payments
$77.09
Companies
49
Transactions
211
Medicare Patients
611
Medicare Billing
$168,930
Payment Breakdown by Category
Consulting$4,268 (47.0%)
Food & Beverage$3,807 (41.9%)
Travel$770.56 (8.5%)
Education$243.04 (2.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,268 | 2 | 47.0% |
| Food and Beverage | $3,807 | 197 | 41.9% |
| Travel and Lodging | $770.56 | 4 | 8.5% |
| Education | $243.04 | 8 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TESARO, Inc. | $2,718 | 5 | $0 (2017) |
| Cardinal Health 414, LLC | $2,570 | 7 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $478.97 | 20 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $286.71 | 15 | $0 (2021) |
| Amgen Inc. | $269.59 | 16 | $0 (2022) |
| Janssen Biotech, Inc. | $241.81 | 10 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $233.88 | 11 | $0 (2021) |
| Puma Biotechnology, Inc. | $214.28 | 7 | $0 (2023) |
| PFIZER INC. | $139.14 | 10 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $128.56 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $77.09 | 4 | ABBVIE INC. ($77.09) |
| 2023 | $66.51 | 4 | ABBVIE INC. ($29.59) |
| 2022 | $258.62 | 12 | AVEO Pharmaceuticals, Inc. ($80.29) |
| 2021 | $1,675 | 80 | E.R. Squibb & Sons, L.L.C. ($372.59) |
| 2020 | $370.25 | 23 | Merck Sharp & Dohme Corporation ($74.78) |
| 2019 | $134.59 | 8 | E.R. Squibb & Sons, L.L.C. ($31.61) |
| 2018 | $703.88 | 36 | Janssen Biotech, Inc. ($174.92) |
| 2017 | $5,802 | 44 | TESARO, Inc. ($2,718) |
All Payment Transactions
211 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/05/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: ONCOLOGY | ||||||
| 04/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2023 | Puma Biotechnology, Inc. | — | Food and Beverage | In-kind items and services | $18.17 | General |
| 08/17/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: ONCOLOGY | ||||||
| 05/22/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Oncology | ||||||
| 05/22/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2022 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $20.01 | General |
| Category: Oncology | ||||||
| 11/01/2022 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Oncology | ||||||
| 07/19/2022 | PFIZER INC. | BOSULIF (Drug), BESPONSA, PAXLOVID | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 07/18/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2022 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $66.99 | General |
| Category: Oncology | ||||||
| 07/14/2022 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Oncology | ||||||
| 07/13/2022 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Food and Beverage | In-kind items and services | $15.36 | General |
| Category: Hematology | ||||||
| 07/11/2022 | MorphoSys, US Inc. | MONJUVI (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Oncology | ||||||
| 07/05/2022 | Sobi, Inc | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/12/2022 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: Oncology | ||||||
| 05/06/2022 | Sun Pharmaceutical Industries Inc. | Odomzo (Drug), YONSA | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Oncology | ||||||
| 02/01/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $23.73 | General |
| Category: Hematology | ||||||
| 12/14/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.67 | General |
| Category: Oncology | ||||||
| 12/08/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $34.55 | General |
| Category: Oncology | ||||||
| 12/02/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2021 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $24.69 | General |
| Category: Oncology | ||||||
| 11/09/2021 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.48 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 145 | 194 | $55,234 | $15,626 |
| 2022 | 3 | 227 | 343 | $91,083 | $35,241 |
| 2021 | 4 | 159 | 964 | $272,598 | $96,621 |
| 2020 | 3 | 80 | 267 | $117,626 | $21,441 |
Total Patients
611
Total Services
1,768
Medicare Billing
$168,930
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 70 | 111 | $26,789 | $7,529 | 28.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 48 | 48 | $15,803 | $4,072 | 25.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 35 | $12,642 | $4,025 | 31.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 90 | 196 | $47,926 | $18,851 | 39.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 105 | 105 | $37,025 | $13,071 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 18 | 28 | $2,716 | $2,139 | 78.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $3,416 | $1,180 | 34.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 94 | 892 | $248,448 | $89,308 | 35.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 32 | 32 | $13,978 | $3,939 | 28.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 21 | 26 | $4,992 | $1,881 | 37.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 12 | 14 | $5,180 | $1,494 | 28.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 43 | 201 | $96,602 | $16,716 | 17.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 23 | 52 | $11,502 | $3,092 | 26.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 14 | 14 | $9,522 | $1,633 | 17.1% |
About Dr. Ajay Mitter, MD
Dr. Ajay Mitter, MD is a Hematology & Oncology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174587307.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ajay Mitter, MD has received a total of $9,089 in payments from pharmaceutical and medical device companies, with $77.09 received in 2024. These payments were reported across 211 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($4,268).
As a Medicare-enrolled provider, Mitter has provided services to 611 Medicare beneficiaries, totaling 1,768 services with total Medicare billing of $168,930. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location San Antonio, TX
- Active Since 04/14/2006
- Last Updated 06/05/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1174587307
Products in Payments
- ZEJULA (Drug) $2,754
- KEYTRUDA (Biological) $254.19
- NERLYNX (Drug) $196.11
- OPDIVO (Biological) $194.89
- FOTIVDA (Drug) $114.80
- Nplate (Biological) $110.47
- VENCLEXTA (Drug) $106.68
- GILOTRIF (Drug) $102.92
- IMBRUVICA (Drug) $99.95
- Stivarga (Drug) $95.07
- PROMACTA (Drug) $86.22
- DARZALEX (Biological) $75.21
- JAKAFI (Drug) $71.37
- LIBTAYO (Biological) $68.85
- KISQALI (Drug) $66.42
- GRANIX (Drug) $62.65
- BOSULIF (Drug) $62.21
- Doptelet (Drug) $56.15
- NINLARO (Drug) $52.71
- Ixempra (Drug) $49.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Antonio
Dr. Timothy Fenske, Md, MD
Hematology & Oncology — Payments: $770,308
Hematology & Oncology $770,308
Dr. Paul Shaughnessy, M.d, M.D
Hematology & Oncology — Payments: $522,755
Hematology & Oncology $522,755
Francis Giles, M.d, M.D
Hematology & Oncology — Payments: $519,610
Hematology & Oncology $519,610
Dr. John Renshaw, M.d, M.D
Hematology & Oncology — Payments: $322,856
Hematology & Oncology $322,856
Dr. Elizabeth Bowhay-Carnes, M.d, M.D
Hematology & Oncology — Payments: $200,175
Hematology & Oncology $200,175
Dr. Marcela Mazo Canola, M.d, M.D
Hematology & Oncology — Payments: $150,233
Hematology & Oncology $150,233